Has Dana Sandrik received payments from drug or device companies?

Yes. Drug and device makers reported $2,578 in general payments to Dana Sandrik across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dana Sandrik did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dana Sandrik come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dana Sandrik

Primary Care · Anthem, AZNPI 1457906380

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 43.5% of the total. Reporting peaked in 2022 at $905 and has fallen 68.6% since, to $285 in 2025.

$2,578in general payments, 2019–2025

Across 102 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Teva Pharmaceuticals USA, Inc.$270
Biohaven Pharmaceuticals, Inc.$237
Novo Nordisk$227
Galderma Laboratories, L.p.$179
Lilly USA, LLC$156
plus $388 from 11 others

What the payments were for

Food & beverage$2,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	56	$1,122
Teva Pharmaceuticals USA, Inc.	12	$270
Biohaven Pharmaceuticals, Inc.	7	$237
Novo Nordisk	2	$227
Galderma Laboratories, L.p.	2	$179
Lilly USA, LLC	4	$156
Biohaven Pharmaceutical Holding Company Ltd.	5	$88
AstraZeneca	1	$86
Takeda Pharmaceuticals U.S.A., Inc.	3	$65
Amgen	2	$38
Antares Pharma, Inc.	2	$23
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$21
GSK	1	$19
Merck	1	$16
Merz North America, Inc.	1	$16
Upsher-smith Laboratories LLC	1	$12
Genentech USA, Inc.	1	$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,578 in reported general payments places this provider in the 85th percentile of 151 primary care providers in Arizona.

See all primary care providers in Arizona →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron OdtOndansetron	89	$1,396

Paid to pharmacies, not to this prescriber.

Other primary care in Anthem

Trey PowrzanasPhoenix$16K
Christine Rocks-LopezPhoenix$14K
Elena KlimovaPhoenix$8K
Albert VillafaniaPhoenix$8K
Daniela HaimovPhoenix$8K
Lea NickolasAvondale$7K
Neena VargheseSacaton$6K
Katy DodtQueen Creek$5K
Mercy GeorgeQueen Creek$5K
Charity CorreaPhoenix$5K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →